Trial Profile
A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the intravenous treatment of adult patients with severe community-acquired bacterial pneumonia and admitted to the intensive care unit
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Cx 611 (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Acronyms SEPCELL
- Sponsors TiGenix
- 14 May 2022 The trial has been completed in Spain, according to European Clinical Trials Database record.
- 01 Feb 2022 Status changed from active, no longer recruiting to completed.
- 12 Dec 2020 This trial has been completed in United Kingdom (Global End Date: 07 Jul 2020), according to European Clinical Trials Database record.